Ceftriaxone Dosage for Community-Acquired Pneumonia

(DC-CAP Trial)

This trial examines the effectiveness and safety of different Ceftriaxone doses for treating community-acquired pneumonia in hospitalized patients not in the ICU. Researchers aim to determine if a 1-gram daily dose works as well as a 2-gram daily dose but with fewer side effects. Suitable participants are those hospitalized with community-acquired pneumonia and currently receiving Ceftriaxone, without needing intensive care or advanced breathing support. As a Phase 4 trial, Ceftriaxone has already received FDA approval and proven effective, and this research seeks to understand its benefits for more patients.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Research has shown that both 1 gram and 2 grams of Ceftriaxone are usually well-tolerated by patients with community-acquired pneumonia. Studies have found no major difference in recovery between the two doses. For example, one study reported a 94.6% cure rate for patients taking 1 gram daily, similar to those taking 2 grams daily.

Regarding side effects, earlier research suggests that lower doses might cause fewer problems. A study comparing the two doses found that patients experienced fewer side effects with the 1 gram dose than with the 2 grams. This suggests the lower dose might be gentler on the body while still being effective.

Ceftriaxone is unique because it offers a potentially more streamlined approach to treating community-acquired pneumonia outside of the intensive care unit. Researchers are exploring different dosing levels—specifically, low-dose (1 gram daily) and moderate-dose (2 grams daily) regimens. Compared to other antibiotics like azithromycin or levofloxacin, ceftriaxone's administration through intravenous infusion allows for consistent delivery directly into the bloodstream, which could lead to faster and more effective results. By adjusting the dose, researchers hope to find the optimal balance that maximizes effectiveness while minimizing potential side effects. This tailored approach could make ceftriaxone a more adaptable and efficient option for treating this common lung infection.

Research has shown that ceftriaxone, an antibiotic, effectively treats pneumonia acquired outside hospitals. This trial will compare two dosages of ceftriaxone: a low dose of 1 gram daily and a moderate dose of 2 grams daily. Studies have found both dosages equally effective in curing the illness. For instance, one study found no significant difference in cure rates between patients taking 1 gram (94.6% cure rate) and those taking 2 grams. Another study showed that the likelihood of treatment failure was low and similar for both doses. Both doses are safe, but the lower dose might cause fewer side effects. Overall, ceftriaxone is a proven treatment for pneumonia, and both doses are effective.¹²³⁴⁶